Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status:
Completed
Trial end date:
2019-07-12
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of
optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with
Tourette Syndrome.